RIGL Rigel Pharmaceuticals Inc.

2.73
-0.03  -1%
Previous Close 2.76
Open 2.75
Price To Book 4.4
Market Cap 454928489
Shares 166,640,472
Volume 1,537,837
Short Ratio
Av. Daily Volume 2,164,039

SEC filingsSee all SEC filings

  1. 8-K - Current report 181163075
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181162995
  3. 8-K - Current report 181142841
  4. 8-K - Current report 181106983
  5. S-8 - Securities to be offered to employees in employee benefit plans 181002436

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 trial to commence 1H 2019.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 trial initiation announced June 26, 2018.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
  2. New Research Coverage Highlights Weight Watchers International, Rudolph Technologies, Lowe's Companies, Net 1 UEPS Technologies, Viasat, and Rigel Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
  3. What does Rigel Pharmaceuticals Inc’s (NASDAQ:RIGL) Balance Sheet Tell Us About Its Future?
  4. Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
  5. Edited Transcript of RIGL earnings conference call or presentation 6-Nov-18 10:00pm GMT
  6. Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
  7. Rigel: 3Q Earnings Snapshot
  8. Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
  9. Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition
  10. Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results
  11. Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
  12. Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  13. How Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Can Impact Your Portfolio Volatility
  14. Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
  15. Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
  16. Rigel to Host Investor & Analyst Day in New York City on October 4, 2018
  17. Rigel to Present at the Cantor Global Healthcare Conference
  18. Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher
  19. Here's Why Rigel Pharmaceuticals, Inc. Jumped Over 20% in August

SEC Filings

  1. 8-K - Current report 181163075
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181162995
  3. 8-K - Current report 181142841
  4. 8-K - Current report 181106983
  5. S-8 - Securities to be offered to employees in employee benefit plans 181002436
  6. 8-K - Current report 181001890
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001472
  8. 8-K - Current report 18872493
  9. 8-K - Current report 18847057
  10. 8-K - Current report 18796210